成纤维细胞生长因子受体
尿路上皮癌
尿路上皮癌
医学
食品药品监督管理局
癌症研究
药品
肿瘤科
内科学
癌症
药理学
成纤维细胞生长因子
膀胱癌
受体
作者
Veronika Weyerer,Markus Eckstein,Arndt Hartmann,Robert Stöhr
出处
期刊:Methods in molecular biology
日期:2023-01-01
卷期号:: 283-291
标识
DOI:10.1007/978-1-0716-3291-8_17
摘要
FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit.
科研通智能强力驱动
Strongly Powered by AbleSci AI